GLENMARK

Glenmark Pharmaceuticals Share PriceGlenmark Pharmaceuticals

₹819.1
23.15 (2.91%)
  • Advice
  • Hold
As on 11 December, 2023 | 19:03 BSE: 532296 NSE: GLENMARKISIN: INE935A01035

Glenmark Pharmaceuticals Performance

Day Range

  • Low 791.75
  • High 830.95
₹ 819.1

52 Week Range

  • Low 369.05
  • High 880.00
₹ 819.1
  • Open Price800.00
  • Previous Close795.95
  • Volume2857825

Start SIP in Glenmark Pharmaceuticals

Start SIP

Glenmark Pharmaceuticals Share Price

  • Over 1 Month 5.3%
  • Over 3 Month 1%
  • Over 6 Month 28.78%
  • Over 1 Year 87.44%

Glenmark Pharmaceuticals Key Statistics

P/E Ratio -117.7
PEG Ratio 1
Market Cap Cr 23,112
Price to Book Ratio 2.3
EPS 55.9
Dividend 0.3
Relative Strength Index 60.02
Money Flow Index 47.82
MACD Signal 4.63
Average True Range 24.65

Glenmark Pharmaceuticals Investment Rating

  • Master Rating:
  • Glenmark Pharms. (Nse) has an operating revenue of Rs. 13,446.55 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 7% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 41%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 19% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Glenmark Pharmaceuticals Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 2,2332,1441,8752,1612,1531,8721,721
Operating Expenses Qtr Cr 1,7631,6591,7211,7231,8261,4781,624
Operating Profit Qtr Cr 471485218439382434162
Depreciation Qtr Cr 50494746464542
Interest Qtr Cr 58625956524074
Tax Qtr Cr 87120-17615917720319
Net Profit Qtr Cr 302272-137431423493206
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 9,2078,756
Operating Expenses Annual Cr 6,7486,453
Operating Profit Annual in Cr 1,4731,688
Depreciation Cr 184160
Interest Annual Cr 207236
Tax Annual Cr 363340
Net Profit Annual Cr 1,2091,998
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 1,4741,216
Cash from Investing Activity Annual Cr -431-897
Cash from Financing Annual Activity Cr -978-305
Net Cash Flow Annual Cr 6414
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 17,87716,739
Fixed Assets Annual Cr 1,9181,861
Total Non Current Assets Annual Cr 20,20118,512
Total Current Assets Annual Cr 4,3854,403
Total Assets Annual Cr 24,58622,914
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 634593
ROE Annual % 712
ROCE Annual % 1111
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 3028
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 3,2073,4023,3013,4643,3122,7202,961
Operating Expenses Qtr Cr 2,7452,7702,7692,8442,7542,3462,556
Operating Profit Qtr Cr 462631605620622432463
Depreciation Qtr Cr 141155147162156147132
Interest Qtr Cr 12111210997836087
Tax Qtr Cr 56160-8818020219797
Net Profit Qtr Cr -8223-428291260193156
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 13,30712,472
Operating Expenses Annual Cr 10,7129,985
Operating Profit Annual in Cr 2,2782,320
Depreciation Cr 611487
Interest Annual Cr 350298
Tax Annual Cr 491448
Net Profit Annual Cr 297942
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 6251,109
Cash from Investing Activity Annual Cr -528-333
Cash from Financing Annual Activity Cr -77-520
Net Cash Flow Annual Cr 19255
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 9,4749,087
Fixed Assets Annual Cr 7,3806,837
Total Non Current Assets Annual Cr 9,4988,801
Total Current Assets Annual Cr 9,8748,282
Total Assets Annual Cr 19,37217,083
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 349334
ROE Annual % 310
ROCE Annual % 1416
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2020

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹819.1
23.15 (2.91%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹786.70
  • 50 Day
  • ₹779.31
  • 100 Day
  • ₹754.62
  • 200 Day
  • ₹685.93
  • 20 Day
  • ₹779.91
  • 50 Day
  • ₹779.78
  • 100 Day
  • ₹784.71
  • 200 Day
  • ₹667.45

Glenmark Pharmaceuticals Resistance and Support

PIVOT
₹813.94
Resistance
First Resistance 836.12
Second Resistance 853.13
Third Resistance 875.32
RSI 60.02
MFI 47.82
MACD Single Line 4.63
MACD 9.32
Support
First Resistance 796.92
Second Resistance 774.73
Third Resistance 757.72

Glenmark Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 2,951,625 55,461,034 18.79
Week 1,846,725 50,563,341 27.38
1 Month 1,620,549 53,105,401 32.77
6 Month 1,319,248 41,701,434 31.61

Glenmark Pharmaceuticals Result Highlights

Glenmark Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8220.66 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2023. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.
Market Cap 23,163
Sales 8,478
Shares in Float 14.95
No of funds 288
Yield 0.31
Book Value 1.26
U/D Vol ratio 1
LTDebt / Equity 15
Alpha 0.2
Beta 0.81

Glenmark Pharmaceuticals

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 46.65%46.65%46.65%46.65%
Mutual Funds 7.3%5.36%5.43%5.64%
Insurance Companies 2.44%3.18%4.41%4.48%
Foreign Portfolio Investors 24.79%25.51%22.47%23.19%
Financial Institutions/ Banks 0.2%0.2%0.2%0.2%
Individual Investors 14.84%15.2%16.9%16.72%
Others 3.78%3.9%3.94%3.12%

Glenmark Pharmaceuticals Management

Name Designation
Mr. Glenn Saldanha Chairman & Managing Director
Mrs. Cherylann Pinto Executive Director - Corporate Affairs
Mr. V S Mani Executive Director & Global CFO
Mr. Rajesh V Desai Non Executive Director
Dr. Brian W Tempest Non Executive Director
Mr. Dipankar Bhattacharjee Non Executive Director
Mr. Bernard Munos Non Executive Director
Mr. Sridhar Gorthi Non Executive Director
Mrs. B E Saldanha Non Executive Director
Mr. D R Mehta Non Executive Director
Ms. Saira Ramasastry Non Executive Director

Glenmark Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Glenmark Pharmaceuticals Corporate Action

Date Purpose Remarks
2023-11-10 Quarterly Results
2023-08-11 Quarterly Results
2023-05-19 Audited Results & Final Dividend
2023-02-10 Quarterly Results
2022-11-11 Quarterly Results

Glenmark Pharmaceuticals MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 63,981
HDFC Mid-Cap Opportunities Fund Growth 47,846
Kotak Equity Arbitrage Fund Growth 28,958
SBI Arbitrage Opportunities Fund Regular Growth 22,370
Aditya Birla Sun Life Flexi Cap Fund Growth 17,029

Glenmark Pharmaceuticals FAQs

What is Share Price of Glenmark Pharmaceuticals ?

Glenmark Pharmaceuticals share price is ₹819 As on 11 December, 2023 | 18:49

What is the Market Cap of Glenmark Pharmaceuticals ?

The Market Cap of Glenmark Pharmaceuticals is ₹23112.4 Cr As on 11 December, 2023 | 18:49

What is the P/E ratio of Glenmark Pharmaceuticals ?

The P/E ratio of Glenmark Pharmaceuticals is -117.7 As on 11 December, 2023 | 18:49

What is the PB ratio of Glenmark Pharmaceuticals ?

The PB ratio of Glenmark Pharmaceuticals is 2.3 As on 11 December, 2023 | 18:49

Q2FY23